A Factorial-Design, Randomised, Double-Blind, Placebo-Controlled, Dose Optimisation Study to Investigate the Safety, Efficacy, Immunogenicity and Pharmacokinetics of ART621 Following Multiple Dose Administration in Subjects Diagnosed With Rheumatoid Arthritis Concomitantly Taking Methotrexate.

Trial Profile

A Factorial-Design, Randomised, Double-Blind, Placebo-Controlled, Dose Optimisation Study to Investigate the Safety, Efficacy, Immunogenicity and Pharmacokinetics of ART621 Following Multiple Dose Administration in Subjects Diagnosed With Rheumatoid Arthritis Concomitantly Taking Methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2010

At a glance

  • Drugs Placulumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Arana Therapeutics
  • Most Recent Events

    • 07 Jan 2010 Actual patient number (27) added as reported by ClinicalTrials.gov.
    • 07 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Actual initiation date changed from Nov 2008 to Feb 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top